Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer

Ji Soo Park, Hyo Song Kim, Yoon Sung Bae, Jae Ho Cheong, SunYoung Rha, Sung Hoon Noh, Hyunki Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The aim of this study is to find the frequency and the role of epidermal growth factor receptor expression as a prognostic biomarker in gastric cancer. Methods: We evaluated the prognostic value and frequency of epidermal growth factor receptor expression and amplification using immunohistochemistry and silver in situ hybridization in a large cohort of curatively resected gastric cancer. Results: Of the total of 935 cases, 294 (31.4%), 101 (10.8%) and 36 (3.9%) patients showed epidermal growth factor receptor 1+, 2+ and 3+ expression on immunohistochemistry, respectively. Epidermal growth factor receptor-positive (2+/3+) patients more frequently had intestinal type than epidermal growth factor receptor-negative (0/1+) patients (82.5 vs. 44.1%, P < 0.001). After adjusting for sex, age, stage and adjuvant chemotherapy, epidermal growth factor receptor-positive patients had a favorable overall survival outcome compared with epidermal growth factor receptor-negative patients (hazard ratio, 0.734; 95% confidence interval, 0.541-0.997; P = 0.047), especially in Stage III disease (hazard ratio, 0.676; 95% confidence interval, 0.472-0.968; P = 0.033). Among the 393 cases available for in situ hybridization, the correlation between immunohistochemistry and in situ hybridization was statistically significant (P = 0.001). Thirteen patients with gene amplification (3.3%) did not show different survival outcome with others (P = 0.359). Conclusion: Epidermal growth factor receptor positivity was an independent favorable prognostic factor for gastric cancer, especially in Stage III disease.

Original languageEnglish
Article numberhyw030
Pages (from-to)507-516
Number of pages10
JournalJapanese Journal of Clinical Oncology
Volume46
Issue number6
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Epidermal Growth Factor Receptor
Stomach Neoplasms
In Situ Hybridization
Immunohistochemistry
Confidence Intervals
Survival
Gene Amplification
Adjuvant Chemotherapy
Silver
Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Park, Ji Soo ; Kim, Hyo Song ; Bae, Yoon Sung ; Cheong, Jae Ho ; Rha, SunYoung ; Noh, Sung Hoon ; Kim, Hyunki. / Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. In: Japanese Journal of Clinical Oncology. 2016 ; Vol. 46, No. 6. pp. 507-516.
@article{548c2a9113624cfbafe02b8a49591cb9,
title = "Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer",
abstract = "Objective: The aim of this study is to find the frequency and the role of epidermal growth factor receptor expression as a prognostic biomarker in gastric cancer. Methods: We evaluated the prognostic value and frequency of epidermal growth factor receptor expression and amplification using immunohistochemistry and silver in situ hybridization in a large cohort of curatively resected gastric cancer. Results: Of the total of 935 cases, 294 (31.4{\%}), 101 (10.8{\%}) and 36 (3.9{\%}) patients showed epidermal growth factor receptor 1+, 2+ and 3+ expression on immunohistochemistry, respectively. Epidermal growth factor receptor-positive (2+/3+) patients more frequently had intestinal type than epidermal growth factor receptor-negative (0/1+) patients (82.5 vs. 44.1{\%}, P < 0.001). After adjusting for sex, age, stage and adjuvant chemotherapy, epidermal growth factor receptor-positive patients had a favorable overall survival outcome compared with epidermal growth factor receptor-negative patients (hazard ratio, 0.734; 95{\%} confidence interval, 0.541-0.997; P = 0.047), especially in Stage III disease (hazard ratio, 0.676; 95{\%} confidence interval, 0.472-0.968; P = 0.033). Among the 393 cases available for in situ hybridization, the correlation between immunohistochemistry and in situ hybridization was statistically significant (P = 0.001). Thirteen patients with gene amplification (3.3{\%}) did not show different survival outcome with others (P = 0.359). Conclusion: Epidermal growth factor receptor positivity was an independent favorable prognostic factor for gastric cancer, especially in Stage III disease.",
author = "Park, {Ji Soo} and Kim, {Hyo Song} and Bae, {Yoon Sung} and Cheong, {Jae Ho} and SunYoung Rha and Noh, {Sung Hoon} and Hyunki Kim",
year = "2016",
month = "6",
day = "1",
doi = "10.1093/jjco/hyw030",
language = "English",
volume = "46",
pages = "507--516",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. / Park, Ji Soo; Kim, Hyo Song; Bae, Yoon Sung; Cheong, Jae Ho; Rha, SunYoung; Noh, Sung Hoon; Kim, Hyunki.

In: Japanese Journal of Clinical Oncology, Vol. 46, No. 6, hyw030, 01.06.2016, p. 507-516.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer

AU - Park, Ji Soo

AU - Kim, Hyo Song

AU - Bae, Yoon Sung

AU - Cheong, Jae Ho

AU - Rha, SunYoung

AU - Noh, Sung Hoon

AU - Kim, Hyunki

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective: The aim of this study is to find the frequency and the role of epidermal growth factor receptor expression as a prognostic biomarker in gastric cancer. Methods: We evaluated the prognostic value and frequency of epidermal growth factor receptor expression and amplification using immunohistochemistry and silver in situ hybridization in a large cohort of curatively resected gastric cancer. Results: Of the total of 935 cases, 294 (31.4%), 101 (10.8%) and 36 (3.9%) patients showed epidermal growth factor receptor 1+, 2+ and 3+ expression on immunohistochemistry, respectively. Epidermal growth factor receptor-positive (2+/3+) patients more frequently had intestinal type than epidermal growth factor receptor-negative (0/1+) patients (82.5 vs. 44.1%, P < 0.001). After adjusting for sex, age, stage and adjuvant chemotherapy, epidermal growth factor receptor-positive patients had a favorable overall survival outcome compared with epidermal growth factor receptor-negative patients (hazard ratio, 0.734; 95% confidence interval, 0.541-0.997; P = 0.047), especially in Stage III disease (hazard ratio, 0.676; 95% confidence interval, 0.472-0.968; P = 0.033). Among the 393 cases available for in situ hybridization, the correlation between immunohistochemistry and in situ hybridization was statistically significant (P = 0.001). Thirteen patients with gene amplification (3.3%) did not show different survival outcome with others (P = 0.359). Conclusion: Epidermal growth factor receptor positivity was an independent favorable prognostic factor for gastric cancer, especially in Stage III disease.

AB - Objective: The aim of this study is to find the frequency and the role of epidermal growth factor receptor expression as a prognostic biomarker in gastric cancer. Methods: We evaluated the prognostic value and frequency of epidermal growth factor receptor expression and amplification using immunohistochemistry and silver in situ hybridization in a large cohort of curatively resected gastric cancer. Results: Of the total of 935 cases, 294 (31.4%), 101 (10.8%) and 36 (3.9%) patients showed epidermal growth factor receptor 1+, 2+ and 3+ expression on immunohistochemistry, respectively. Epidermal growth factor receptor-positive (2+/3+) patients more frequently had intestinal type than epidermal growth factor receptor-negative (0/1+) patients (82.5 vs. 44.1%, P < 0.001). After adjusting for sex, age, stage and adjuvant chemotherapy, epidermal growth factor receptor-positive patients had a favorable overall survival outcome compared with epidermal growth factor receptor-negative patients (hazard ratio, 0.734; 95% confidence interval, 0.541-0.997; P = 0.047), especially in Stage III disease (hazard ratio, 0.676; 95% confidence interval, 0.472-0.968; P = 0.033). Among the 393 cases available for in situ hybridization, the correlation between immunohistochemistry and in situ hybridization was statistically significant (P = 0.001). Thirteen patients with gene amplification (3.3%) did not show different survival outcome with others (P = 0.359). Conclusion: Epidermal growth factor receptor positivity was an independent favorable prognostic factor for gastric cancer, especially in Stage III disease.

UR - http://www.scopus.com/inward/record.url?scp=84991829569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991829569&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyw030

DO - 10.1093/jjco/hyw030

M3 - Article

VL - 46

SP - 507

EP - 516

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

M1 - hyw030

ER -